This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Investment legend Peter Lynch thinks it is a mistake to time the market and run to the hills in anticipation of a correction.

Stocks rose as traders appeared to shake off the latest tariff threat from President Donald Trump while they awaited key ...

Encryption Consulting, a global leader in applied cryptography and cybersecurity solutions, announced significant updates to its CodeSign Secure platform, a comprehensive code-signing solution ...

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

Co's stock has reached a 52-week low, dipping to $85.71. This downturn reflects a significant shift from the previous year, with the pharmaceutical giant experiencing a 1-year change of -31.59%.

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The rise of misinformation online has helped fringe health ideas go mainstream and eased RFK Jr.'s path to confirmation as ...

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.